Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide Treatment for IgG4-RD
NCT03715699Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jul 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of leflunomide in IgG4-related disease (IgG4-RD) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Response of Leflunomide treatment for IgG4-RD at 1 year. Status: unknown.
02
Drugs
leflunomide
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT03715699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03715699.